新型冠状病毒肺炎与肺动脉高压：早期数据及诸多问题 - Suppr

Suppr

超能文献

COVID-19 and Pulmonary Arterial Hypertension: Early Data and Many Questions.

作者信息

Farha Samar, Heresi Gustavo A

机构信息

Department of Pulmonary and Critical Care Medicine, Respiratory Institute, Cleveland Clinic, Cleveland, Ohio.

出版信息

Ann Am Thorac Soc. 2020 Dec;17(12):1528-1530. doi: 10.1513/AnnalsATS.202008-1014ED.

DOI:10.1513/AnnalsATS.202008-1014ED

PMID:33258672

原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC7706598/

Abstract

摘要

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/f42c/7706598/de2c648a1653/AnnalsATS.202008-1014EDf1.jpg

相似文献

COVID-19 and Pulmonary Arterial Hypertension: Early Data and Many Questions.新型冠状病毒肺炎与肺动脉高压：早期数据及诸多问题

Ann Am Thorac Soc. 2020 Dec;17(12):1528-1530. doi: 10.1513/AnnalsATS.202008-1014ED.

COVID-19 Experience and Pulmonary Arterial Hypertension: Do Earlier Theses and New Data Still Match?2019冠状病毒病的经历与肺动脉高压：早期观点与新数据是否仍然相符？

Ann Am Thorac Soc. 2021 Jun;18(6):1080-1081. doi: 10.1513/AnnalsATS.202012-1498LE.

Reply: COVID-19 Experience and Pulmonary Arterial Hypertension: Do Earlier Theses and New Data Still Match?回复：新型冠状病毒肺炎的经验与肺动脉高压：早期论点与新数据是否依然相符？

Ann Am Thorac Soc. 2021 Jun;18(6):1081-1082. doi: 10.1513/AnnalsATS.202102-117LE.

Endothelin receptor antagonists for pulmonary arterial hypertension and COVID-19: Friend or foe?用于肺动脉高压和新冠肺炎的内皮素受体拮抗剂：是友还是敌？

J Heart Lung Transplant. 2020 Jul;39(7):729-730. doi: 10.1016/j.healun.2020.04.007. Epub 2020 Apr 17.

Clinical course of COVID-19 in pulmonary arterial hypertension patients.肺动脉高压患者感染新型冠状病毒肺炎的临床病程

Rev Esp Cardiol (Engl Ed). 2020 Sep;73(9):775-778. doi: 10.1016/j.rec.2020.05.015. Epub 2020 May 30.

The Outcome of Patients with Pulmonary Arterial Hypertension and Chronic Thromboembolic Pulmonary Hypertension during the COVID-19 Pandemic.COVID-19 大流行期间肺动脉高压和慢性血栓栓塞性肺动脉高压患者的结局。

Crit Pathw Cardiol. 2023 Jun 1;22(2):60-64. doi: 10.1097/HPC.0000000000000317. Epub 2023 Mar 23.

Pulmonary arterial thrombosis as an important complication of COVID-19 pulmonary disease: letter to the editor.肺动脉血栓形成作为新型冠状病毒肺炎肺部疾病的重要并发症：致编辑的信

Virchows Arch. 2020 Sep;477(3):467-468. doi: 10.1007/s00428-020-02896-4.

Integrated clinical role of echocardiography in patients with COVID-19 disease.超声心动图在新冠病毒疾病患者中的综合临床作用

Heart. 2020 Dec;106(23):1864. doi: 10.1136/heartjnl-2020-318309. Epub 2020 Oct 14.

The pulmonary circuit dynamics in COVID-19!新型冠状病毒肺炎中的肺循环动力学！

J Anesth. 2021 Feb;35(1):161. doi: 10.1007/s00540-020-02869-6. Epub 2020 Oct 31.

Coronavirus SARS-Cov-2 and arterial hypertension - facts and myths.新型冠状病毒SARS-CoV-2与动脉高血压——事实与误解

Pol Merkur Lekarski. 2020 Jun 17;48(285):195-198.

引用本文的文献

Potential therapeutic targets for COVID-19 complicated with pulmonary hypertension: a bioinformatics and early validation study.新型冠状病毒肺炎合并肺动脉高压的潜在治疗靶点：一项生物信息学及早期验证研究

Sci Rep. 2024 Apr 23;14(1):9294. doi: 10.1038/s41598-024-60113-7.

Interaction of Biochemical Processes between Chronic Obstructive Pulmonary Disease (COPD), Pulmonary Arterial Hypertension (PAH), and Coronavirus Disease 2019 (COVID-19).慢性阻塞性肺疾病（COPD）、肺动脉高压（PAH）和 2019 年冠状病毒病（COVID-19）之间生化过程的相互作用。

Pol J Microbiol. 2023 Jun 14;72(2):143-154. doi: 10.33073/pjm-2023-015. eCollection 2023 Jun 1.

Human Endogenous Retrovirus, SARS-CoV-2, and HIV Promote PAH via Inflammation and Growth Stimulation.人类内源性逆转录病毒、SARS-CoV-2 和 HIV 通过炎症和生长刺激促进 PAH。

Int J Mol Sci. 2023 Apr 18;24(8):7472. doi: 10.3390/ijms24087472.

COVID-19 in Patients with Chronic Lung Disease.慢性肺病患者中的 COVID-19 。

Clin Chest Med. 2023 Jun;44(2):385-393. doi: 10.1016/j.ccm.2022.11.013. Epub 2022 Nov 22.

Preventative practices and effects of the COVID-19 pandemic on caregivers of children with pediatric pulmonary hypertension.COVID-19 大流行对儿童肺高血压患儿照护者的预防措施和影响。

BMC Public Health. 2022 Dec 9;22(1):2305. doi: 10.1186/s12889-022-14651-2.

The COVID-19 pandemic and pulmonary arterial hypertension in Italy: adaptation, outcomes and valuable lessons learned.意大利的 COVID-19 大流行与肺动脉高压：适应、结果和宝贵经验教训。

Eur Respir J. 2022 Oct 6;60(4). doi: 10.1183/13993003.00796-2022. Print 2022 Oct.

Different Aspects of Emetine's Capabilities as a Highly Potent SARS-CoV-2 Inhibitor against COVID-19.吐根碱作为一种高效的抗新冠病毒SARS-CoV-2抑制剂的多方面能力

ACS Pharmacol Transl Sci. 2022 May 23;5(6):387-399. doi: 10.1021/acsptsci.2c00045. eCollection 2022 Jun 10.

Apelin Alleviates Meniscus Endothelial Cell Apoptosis in Osteoarthritis.Apelin 减轻骨关节炎中半月板内皮细胞凋亡。

Dis Markers. 2022 Jan 13;2022:3556372. doi: 10.1155/2022/3556372. eCollection 2022.

Potential long-term effects of SARS-CoV-2 infection on the pulmonary vasculature: a global perspective.SARS-CoV-2 感染对肺血管的潜在长期影响：全球视角。

Nat Rev Cardiol. 2022 May;19(5):314-331. doi: 10.1038/s41569-021-00640-2. Epub 2021 Dec 6.

Cardiovascular disease in SARS-CoV-2 infection.严重急性呼吸综合征冠状病毒2感染中的心血管疾病

Clin Transl Immunology. 2021 Sep 7;10(9):e1343. doi: 10.1002/cti2.1343. eCollection 2021.

本文引用的文献

A Survey-based Estimate of COVID-19 Incidence and Outcomes among Patients with Pulmonary Arterial Hypertension or Chronic Thromboembolic Pulmonary Hypertension and Impact on the Process of Care.基于调查的肺动脉高压或慢性血栓栓塞性肺动脉高压患者 COVID-19 发病率和结局的估计及其对治疗过程的影响。

Ann Am Thorac Soc. 2020 Dec;17(12):1576-1582. doi: 10.1513/AnnalsATS.202005-521OC.

Pulmonary pathology and COVID-19: lessons from autopsy. The experience of European Pulmonary Pathologists.肺脏病理学与 COVID-19：尸检获得的启示。欧洲肺脏病理学家的经验。

Virchows Arch. 2020 Sep;477(3):359-372. doi: 10.1007/s00428-020-02886-6. Epub 2020 Jul 9.

Letter to the Editor regarding "Could pulmonary arterial hypertension patients be at lower risk from severe COVID-19?".致编辑的信：关于“肺动脉高压患者感染重症 COVID-19 的风险是否较低？”

Pulm Circ. 2020 May 14;10(2):2045894020925761. doi: 10.1177/2045894020925761. eCollection 2020 Apr-Jun.

Pulmonary Vascular Endothelialitis, Thrombosis, and Angiogenesis in Covid-19.新型冠状病毒肺炎的肺血管内皮细胞炎症、血栓形成和血管生成。

N Engl J Med. 2020 Jul 9;383(2):120-128. doi: 10.1056/NEJMoa2015432. Epub 2020 May 21.

Home Nitric Oxide Therapy for COVID-19.用于治疗新冠肺炎的家庭一氧化氮疗法。

Am J Respir Crit Care Med. 2020 Jul 1;202(1):16-20. doi: 10.1164/rccm.202005-1906ED.

Could pulmonary arterial hypertension patients be at a lower risk from severe COVID-19?肺动脉高压患者患重症 COVID-19 的风险会更低吗？

Pulm Circ. 2020 Apr 27;10(2):2045894020922799. doi: 10.1177/2045894020922799. eCollection 2020 Apr-Jun.

Outpatient Inhaled Nitric Oxide in a Patient with Vasoreactive Idiopathic Pulmonary Arterial Hypertension and COVID-19 Infection.一名患有血管反应性特发性肺动脉高压和新冠病毒感染患者的门诊吸入一氧化氮治疗

Am J Respir Crit Care Med. 2020 Jul 1;202(1):130-132. doi: 10.1164/rccm.202004-0937LE.

Differentiating COVID-19 Pneumonia From Acute Respiratory Distress Syndrome and High Altitude Pulmonary Edema: Therapeutic Implications.鉴别新型冠状病毒肺炎与急性呼吸窘迫综合征和高原肺水肿：治疗意义

Circulation. 2020 Jul 14;142(2):101-104. doi: 10.1161/CIRCULATIONAHA.120.047915. Epub 2020 May 5.

Endothelial cell infection and endotheliitis in COVID-19.新型冠状病毒肺炎中的内皮细胞感染与内皮炎

Lancet. 2020 May 2;395(10234):1417-1418. doi: 10.1016/S0140-6736(20)30937-5. Epub 2020 Apr 21.

AMP-activated Protein Kinase Phosphorylation of Angiotensin-Converting Enzyme 2 in Endothelium Mitigates Pulmonary Hypertension.AMP 激活的蛋白激酶对血管内皮细胞血管紧张素转换酶 2 的磷酸化作用可减轻肺动脉高压。

Am J Respir Crit Care Med. 2018 Aug 15;198(4):509-520. doi: 10.1164/rccm.201712-2570OC.

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验